Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants

Figure 1 Patient selection and flow. AC: Anticoagulants; DOAC: Direct oral anticoagulants; HPB: Heparin bridge.

Figure 2 Thirty-day post-polypectomy bleeding in controls (n = 218), anticoagulants users (n = 218) and subgroups of warfarin (n = 145) and direct oral anticoagulants users [n = 73: rivaroxaban (n = 38), dabigatran (n = 18), and apixaban (n = 15)]. P-values for comparison of each group with controls and for comparison of direct oral anticoagulants users with warfarin users. AC: Anticoagulants; DOAC: Direct oral anticoagulants.

Figure 3 Post-polypectomy bleeding according to the three main anticoagulants management strategies in anticoagulants (A), warfarin (B), and direct oral anticoagulants (C) users. For the 218 patients, 102 patients (46.8%) in the discontinuing anticoagulants with heparin bridge group, 93 (42.7%) in the continuing anticoagulants group, and 23 (10.6%) in the discontinuing anticoagulants without heparin bridge group. AC: Anticoagulants; DOAC: Direct oral anticoagulants; HPB: Heparin bridge.

Figure 4 Association of post-polypectomy bleeding rate with duration of heparin bridge in anticoagulants, warfarin, and direct oral anticoagulants users. AC: Anticoagulants; WF: Warfarin; DOAC: Direct oral anticoagulants; HPB: Heparin bridge; PPB: Post-polypectomy bleeding.